Natural killer cell therapy - Takara Bio

Drug Profile

Natural killer cell therapy - Takara Bio

Alternative Names: NK cell therapy - Takara Bio

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takara Bio
  • Developer Kyoto Prefectural University of Medicine; Takara Bio
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Gastrointestinal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Refractory metastatic disease, Second-line therapy or greater) in Japan (IV, Infusion)
  • 01 Jul 2014 Phase-I clinical trials in Gastrointestinal cancer (Recurrent, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in Japan (IV)
  • 07 Apr 2014 Interim adverse events and efficacy data from a phase I trial in Gastrointestinal cancer presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR - 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top